MARKET

EIKN

EIKN

Eikon Therapeutics
NASDAQ
5.31
-0.04
-0.75%
After Hours: 5.40 +0.09 +1.69% 19:30 10/30 EDT
OPEN
5.27
PREV CLOSE
5.35
HIGH
5.40
LOW
5.01
VOLUME
553.13K
TURNOVER
--
52 WEEK HIGH
17.40
52 WEEK LOW
5.01
MARKET CAP
287.62M
P/E (TTM)
-0.9533
1D
5D
1M
3M
1Y
5Y
1D
Eikon Therapeutics Advances EIK1005 Cancer Trial, Sharpening Its Precision Oncology Story
TipRanks · 2d ago
Brian Cheng Initiates Buy on Eikon Therapeutics, Citing Advancing Oncology Pipeline and Strategic PARP1/WRN Programs
TipRanks · 5d ago
Eikon Therapeutics: Emerging PARP1 and WRN Data Support Buy Rating with Unchanged $23 Price Target
TipRanks · 6d ago
Eikon Therapeutics Highlights Promising Lung Cancer Trial Data
TipRanks · 6d ago
Weekly Report: what happened at EIKN last week (1019-1023)?
Weekly Report · 6d ago
Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting
Benzinga · 6d ago
Eikon Therapeutics presents updated EIK1001 data at ESMO
TipRanks · 6d ago
Eikon Therapeutics Highlights Promising PARP1 and WRN Data
TipRanks · 10/23 13:49
More
About EIKN
Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company advancing a pipeline of potential therapies for patients with unmet medical needs. The Company has clinical programs at various stages of development, and active discovery efforts in oncology and neurologic disease. Its pipeline includes EIK100, EIK1003, EIK1004, EIK1005, EIK1006, and the ARv7 Program. EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses. EIK1003 and EIK1004 are selective PARP1 inhibitors. These product candidates are designed to inhibit PARP1 while sparing PARP2, thereby promoting tumor regression by targeting the DNA damage response of cancer cells. EIK1005 is designed to inhibit the WRN helicase and is our first internally developed program to advance into clinical studies. EIK1006 is being investigated as a potential next-generation AR antagonist with activity against multiple clinically emergent variants of AR.

Webull offers Eikon Therapeutics,Inc stock information, including NASDAQ: EIKN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIKN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EIKN stock methods without spending real money on the virtual paper trading platform.